Yan Leyfman, Co-founder and executive director of MedNews Week, shared a LinkedIn post about recent article V. Tabar and colleagues authored:
“Promising news in Parkinson’s research!
Researchers at Memorial Sloan Kettering Cancer Center report results from a phase I clinical trial (NCT04802733) using bemdaneprocel, an off-the-shelf dopaminergic progenitor cell therapy derived from human embryonic stem cells.
Key highlights:
- 12 patients received cell grafts into the putamen (low-dose vs high-dose cohorts)
- No adverse events linked to the therapy
- Increased 18F-DOPA PET uptake at 18 months
- High-dose group saw an average 23-point improvement in MDS-UPDRS Part III OFF scores
- No graft-induced dyskinesias
These findings show encouraging safety and early efficacy signals, paving the way for larger trials.”
Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
Authors: V. Tabar et al.
